

**Supplementary Table 1** Data resource used in the current study

Category	Resource	URL
List of antihypertensive drugs	WHO Collaborating Centre for Drug Statistics Methodology	<a href="https://www.whocc.no/">https://www.whocc.no/</a>
Identification of targeted gene	Drugbank	<a href="https://go.drugbank.com/">https://go.drugbank.com/</a>
Genetic instruments for targeted gene expression in blood	eQTLGen Consortium	<a href="https://www.eqtlgen.org/">https://www.eqtlgen.org/</a>
Systolic blood pressure GWAS	GRASP	<a href="https://grasp.nhlbi.nih.gov/FullResults.aspx">https://grasp.nhlbi.nih.gov/FullResults.aspx</a>
Breast cancer GWAS	Breast Cancer Association Consortium	<a href="https://bcac.ccgmedsch.cam.ac.uk/bcacdata/oncoarray/oncoarray-and-combined-summary-result/">https://bcac.ccgmedsch.cam.ac.uk/bcacdata/oncoarray/oncoarray-and-combined-summary-result/</a>
MR association between targeted gene expression in other tissue and risk of breast cancer	Exploiting the GTEx resources to decipher the mechanisms at GWAS loci	<a href="https://zenodo.org/record/3942704#.Ya3sANDMKUn">https://zenodo.org/record/3942704#.Ya3sANDMKUn</a>
Differential gene expression	Expression Atlas	<a href="https://www.ebi.ac.uk/gxa/home">https://www.ebi.ac.uk/gxa/home</a>

**Supplementary Table 2** Genes targeted by antihypertensive medications in DrugBank

Drug Class	Drug subclass	Medication Subclass	ATC Code	Drug name	ATC Code	Target Gene(s)
Antihypertensives	Anti-adrenergic agents, centrally-acting	Rauwolfia alkaloids	C02AA	rescinnamine	C02AA01	ACE
				reserpine	C02AA02	BIRC5, SLC18A1, SLC18A2
				rauwolfia alkaloids	C02AA04	SLC18A2
				deserpidine	C02AA05	SLC18A2
				methoserpidine	C02AA06	
				bietaserpine	C02AA07	
	Methyldopa	C02AB		methyldopa	C02AB01, C02AB02	ADRA2A, DDC
	Imidazoline receptor agonists	C02AC		clonidine	C02AC01	ADRA2A, ADRA2C, ADRA1A, ADRA2B, ADRA1B, ADRA1D
				guanfacine	C02AC02	ADRA2B, ADRA2A
				tolonidine	C02AC04	
				moxonidine	C02AC05	ADRA2A, NISCH
				rilmenidine	C02AC06	ADRA2A
	Anti-adrenergic agents, ganglion-blocking	Sulfonium derivatives	C02BA	trimetaphan	C02BA01	CHRNA10
		Secondary and tertiary amines	C02BB	mecamylamine	C02BB01	CHRNA2, CHRNA4, CHRNB2, CHRNA7
	Anti-adrenergic agents, peripherally-acting	Alpha-adrenoreceptor antagonists	C02CA	prazosin	C02CA01	ADRA1A, ADRA1B, ADRA1D, KCNH2, ADRA2A, ADRA2B
				indoramin	C02CA02	ADRA1A
				trimazosin	C02CA03	
				doxazosin	C02CA04	ADRA1A, ADRA1B, ADRA1D, KCNH2, KCNH6, KCNH7
				urapidil	C02CA06	
	Guanidine derivatives	C02CC		betanidine	C02CC01	KCNJ1, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
				guanethidine	C02CC02	SLC6A2
				guanoxan	C02CC03	
				debrisoquine	C02CC04	SLC6A2

				guanoclor	C02CC05	
				guanazodine	C02CC06	
				guanoxabenz	C02CC07	
arteriolar smooth muscle, agents acting on	Thiazide derivatives	C02DA	diazoxide	C02DA01	CA1, CA2, KCNMA1, KCNJ11, ATP1A1	
	Hydrazinophthalazine derivatives	C02DB	dihydralazine	C02DB01		
			hydralazine	C02DB02	P4HA1, AOC3, HIF1A	
			endralazine	C02DB03		
			cadralazine	C02DB04		
	Pyrimidine derivatives	C02DC	minoxidil	C02DC01	PTGS1, REN, KCNJ1	
other antihypertensives	Nitroferricyanide derivatives	C02DD	nitroprusside	C02DD01	NPR1	
	Guanidine derivatives	C02DG	pinacidil	C02DG01		
	Alkaloids, excl. rauwolfia	C02KA	veratrum	C02KA01		
	Tyrosine hydroxylase inhibitors	C02KB	metirosine	C02KB01	TH	
	MAO inhibitors	C02KC	pargyline	C02KC01	MAOB, MAOA	
	Serotonin antagonists	C02KD	ketanserin	C02KD01	HTR2A	
	Antihypertensives for pulmonary arterial hypertension	C02KX	bosentan	C02KX01	EDNRB, EDNRA	
			ambrisentan	C02KX02	EDNRB, EDNRA	
			sitaxentan	C02KX03	EDNRB, EDNRA	
			macitentan	C02KX04	EDNRB, EDNRA	
			riociguat	C02KX05	GUCY1A2	
ACEi	ACE inhibitors, plain	ACE inhibitors, plain	C09AA	captopril	C09AA01	MMP9, ACE, MMP2, LTA4H, BDKRB1
				enalapril	C09AA02	ACE
				lisinopril	C09AA03	ACE, REN
				perindopril	C09AA04	ACE, SFRP4
				ramipril	C09AA05	ACE, BDKRB1
				quinapril	C09AA06	ACE
				benazepril	C09AA07	ACE
				cilazapril	C09AA08	ACE

				fosinopril	C09AA09	ACE
				trandolapril	C09AA10	ACE
				spirapril	C09AA11	ACE
				delapril	C09AA12	
				moexipril	C09AA13	ACE
				temocapril	C09AA14	ACE
				zofenopril	C09AA15	ACE
				imidapril	C09AA16	
ARBs	Angiotensin ii receptor blockers (ARBs), plain	Angiotensin II receptor blockers (ARBs), plain	C09CA	losartan	C09CA01	AGTR1
				eprosartan	C09CA02	AGTR2
				valsartan	C09CA03	AGTR3
				irbesartan	C09CA04	AGTR1, JUN
				tasosartan	C09CA05	AGTR1, AGTR2
				candesartan	C09CA06	AGTR1
				telmisartan	C09CA07	AGTR1, PPARG
				olmesartan medoxomil	C09CA08	AGTR1
				azilsartan medoxomil	C09CA09	AGTR2
				fimasartan	C09CA10	AGTR3
			C09XA	remikiren	C09XA01	REN
				aliskiren	C09XA02	REN
CCBs	Selective calcium channel blockers with mainly vascular effects	Dihydropyridine derivatives	C08CA	amlodipine	C08CA01	CACNA1I, CA1, CACNB1, CACNA1C, SMPD1, CACNA1B, CACNA2D3
				felodipine	C08CA02	CALM1, CACNA1C, NR3C2, CACNA2D1, CACNA1H, TNNC1, CACNB2, CACNA1S, CACNA1D, CACNA2D2, PDE1B, PDE1A, TNNC2
				isradipine	C08CA03	CACNA1C, CACNA2D1, CACNA1H, CACNB2, CACNA1S, CACNA1D, CACNA2D2

			nicardipine	C08CA04	CHRM3, CHRM1, CHRM5, CHRM4, CALM1, CACNA1C, ADRA1A, CHRM2, ADRA1B, CACNA2D1, ADRA1D, CACNB2, CACNA1D, PDE1B, PDE1A
			nifedipine	C08CA05	CALM1, CACNA1C, NR1I2, CACNB2, CACNA1S, CACNA1D, KCND3, CACNA1G, CACNA1H, CACNA1I
			nimodipine	C08CA06	CACNB1, CACNA1C, NR3C2, CACNB2, CACNA1S, CACNB4, CACNA1F, CACNB3, CACNA1D, AHR
			nisoldipine	C08CA07	CACNA1C, CACNA2D1, CACNB2, CACNA1S, CACNA1D
			nitrendipine	C08CA08	CACNA1C, CACNA2D1, CACNA1H, CACNB2, CACNA1S, CACNA1D, CACNA2D2
			lacidipine	C08CA09	CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CACNA1A
			nilvadipine	C08CA10	CACNA1C, CACNA2D1, CACNB2, CACNA1S, CACNA1D, CACNA2D3
			manidipine	C08CA11	CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CACNA1A, CACNA1G, CACNA1H, CACNA1I
			barnidipine	C08CA12	
			lercanidipine	C08CA13	CACNG1
			cilnidipine	C08CA14	CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CACNA1A
			benidipine	C08CA15	CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CACNA1A, CACNA1G, CACNA1H, CACNA1I
			clevidipine	C08CA16	CACNA1C, CACNA1S, CACNA1F, CACNA1D
	Other selective calcium channel blockers with mainly vascular effects	C08CX	mibepradil	C08CX01	CACNA1I, CACNB1, CACNA1C, CACNA1G, CACNA1H, CACNB2, CACNA1S, CACNB4, CACNA1F, CACNB3, CACNA1D
Selective calcium channel blockers with direct cardiac effects	Phenylalkylamine derivatives	C08DA	verapamil	C08DA01	KCNH2, CACNA1A, CACNA1C, CACNA1G, ADRA1A, ADRA1B, KCNJ11, ADRA1D, SLC6A4, CACNA1H, CACNA1B
			gallopamil	C08DA02	
	Benzothiazepine derivatives	C08DB	diltiazem	C08DB01	CACNA1C, CACNG1
		C08EA	fendiline	C08EA01	

	Non-selective calcium channel blockers	Phenylalkylamine derivatives		bepridil	C08EA02	KCNH2, CACNA1A, CALM1, KCNQ1, ATP1A1, CACNA1H, TNNC1, CACNA2D2, PDE1B, PDE1A
		Other non-selective calcium channel blockers	C08EX	lidoflazine	C08EX01	
				perhexiline	C08EX02	KCNH2, CPT2, CPT1A
Beta blocker	Beta blocking agents	Beta blocking agents, non-selective	C07AA	alprenolol	C07AA01	ADRB1, HTR1A, ADRB2, ADRB3
				oxprenolol	C07AA02	ADRB1, ADRB2, ADRB3
				pindolol	C07AA03	ADRB1, HTR1A, ADRB2, HTR1B, ADRB3
				propranolol	C07AA05	ADRB1, HTR1A, ADRB2, HTR1B, ADRB3
				timolol	C07AA06	ADRB1, ADRB2, E
				sotalol	C07AA07	KCNH2, ADRB1, ADRB2
				nadolol	C07AA12	ADRB1, ADRB2
				mepindolol	C07AA14	
				carteolol	C07AA15	ADRB1, ADRB2
				tertatolol	C07AA16	
				bopindolol	C07AA17	ADRB1, HTR1A, ADRB2, HTR1B, ADRB3
				bupranolol	C07AA19	ADRB1, ADRB2, ADRB3
				penbutolol	C07AA23	ADRB1, HTR1A, ADRB2, HTR1B
				cloranolol	C07AA27	
	Beta blocking agents	Beta blocking agents, selective	C07AB	practolol	C07AB01	ADRB1
				metoprolol	C07AB02	ADRB1, ADRB2
				atenolol	C07AB03	ADRB1, ADRB2
				acebutolol	C07AB04	ADRB1, ADRB2
				betaxolol	C07AB05	ADRB1, ADRB3
				bevantolol	C07AB06	ADRB1, ADRA1A, ADRB2
				bisoprolol	C07AB07	ADRB1, ADRB2
				celiprolol	C07AB08	ADRB1, ADRA2A, ADRA2C, ADRA2B, ADRB2, ADRB3
				esmolol	C07AB09	ADRB1
				epanolol	C07AB10	
				s-atenolol	C07AB11	
				nebivolol	C07AB12	ADRB1, ADRB2, ADRB3
				talinolol	C07AB13	
				landiolol	C07AB14	

	Beta blocking agents	Alpha and beta blocking agents	C07AG	labetalol	C07AG01	ADRB1, ADRB2, ADRA1A, ADRA1B, ADRA1D
				carvedilol	C07AG02	KCNH2, VEGFA, ADRB1, NDUFC2, ADRA2A, ADRA2C, ADRA1A, ADRA2B, ADRA1B, ADRB2, ADRA1D, NPPB, SELE, GJA1, VCAM1, HIF1A, KCNJ4, KCNJ2
Diuretic	Low-ceiling diuretics, thiazides	Thiazides, plain	C03AA	bendroflumethiazide	C03AA01	CA1, CA2, SLC12A3, CA4, KCNMA1
				hydroflumethiazide	C03AA02	CA1, CA2, SLC12A1, CA4, KCNMA1, ATP1A1, CA12, CA9, CA7
				hydrochlorothiazide	C03AA03	SLC12A3, KCNMA1
				chlorothiazide	C03AA04	CA1, CA2, SLC12A3
				polythiazide	C03AA05	SLC12A3
				trichlormethiazide	C03AA06	CA1, CA2, SLC12A3, CA4, ATP1A1
				cyclopenthiazide	C03AA07	
				methyclothiazide	C03AA08	CA1, CA2, SLC12A1, CA4
				cyclothiazide	C03AA09	FXYD2, CA1, CA2, SFRP4, CA13, CA14, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9
				mebutizide	C03AA13	
High-ceiling diuretics	Sulfonamides, plain	C03BA	Sulfonamides, plain	quinethazone	C03BA02	CA1, SLC12A2, CA2, SLC12A3, SLC12A1
				clopamide	C03BA03	
				chlortalidone	C03BA04	CA1, SLC12A1
				mefruside	C03BA05	
				clofenamide	C03BA07	
				metolazone	C03BA08	SLC12A3
				meticrane	C03BA09	
				xipamide	C03BA10	
				indapamide	C03BA11	SLC12A3
				clorexolone	C03BA12	
				fenquizone	C03BA13	
			Mercurial diuretics	mersalyl	C03BC01	SLC16A1, AQP1, ALPL
			Xanthine derivatives	theobromine	C03BD01	ADORA1, PDE4B, ADORA2A
			Other low-ceiling diuretics	cicletanine	C03BX03	
			Sulfonamides, plain	furosemide	C03CA01	CA2, SLC12A1, GPR35
				bumetanide	C03CA02	SLC12A5, SLC12A2, SLC12A1, SLC12A4, CFTR

			piretanide	C03CA03	SLC12A1
			torasemide	C03CA04	SLC12A2, SLC12A1
Aryloxyacetic acid derivatives	C03CC	etacrynic acid	C03CC01	SLC12A1, ATP1A1, GSTP1, LEF1	
		tienilic acid	C03CC02		
Pyrazolone derivatives	C03CD	muzolimine	C03CD01		
Other high-ceiling diuretics	C03CX	etozolin	C03CX01		
Potassium-sparing agents	Aldosterone antagonists	C03DA	spironolactone	C03DA01	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8, CYP11B2, CYP17A1, NR1I2, NR3C1, NR3C2, PGR, SHBG, SRD5A1, SRD5A2, SRD5A3
			potassium canrenoate	C03DA02	
			canrenone	C03DA03	
			eplerenone	C03DA04	NR3C2
			amiloride	C03DB01	AOC1, ASIC1, ASIC2, PLAU, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC9A1
Other diuretics	Vasopressin antagonists	C03XA	triamterene	C03DB02	SCNN1A, SCNN1B, SCNN1D, SCNN1G
			tolvaptan	C03XA01	AVPR1A, AVPR2
			conivaptan	C03XA02	AVPR1A, AVPR3

**Supplementary Table 3** MR association between drug target gene expression in blood and systolic blood pressure

Gene	Probe Chr	Probe_bp	topSNP	topSNP_P_chr	topSNP_bp	Effect_allele	Other_allele	Freq_Effect_allele	eQTL association				SBP association			MR association			HEIDI Test	
									beta	se	p	F_statistics	beta	se	p	beta	se	p	p_HEIDI	nsnp
P4HA1	10	74811853	rs6480668	10	74849326	G	A	0.07	0.183	0.016	3.35E-32	139.5	0.304	0.061	7.17E-07	1.655	0.362	4.82E-06	4.41E-02	3
ACE	17	61576813	rs4308	17	61559625	A	G	0.38	0.075	0.009	2.84E-17	71.5	0.273	0.031	3.11E-18	3.639	0.600	1.35E-09	1.10E-01	17
SLC12A2	5	127472419	rs17764730	5	127357526	T	C	0.22	-0.186	0.009	3.2E-86	387.3	-0.208	0.035	4.49E-09	1.119	0.199	1.85E-08	4.27E-02	20
AOC1	7	150540153	rs7806458	7	150476888	G	A	0.36	0.669	0.008	0.00E+00	6991.5	0.078	0.031	1.27E-02	0.117	0.047	1.28E-02	9.06E-02	20
SCNN1D	1	1221612	rs11804831	1	1194804	C	T	0.15	-0.133	0.012	4.69E-30	129.7	-0.161	0.041	6.90E-05	1.208	0.321	1.72E-04	1.13E-02	20
SLC12A1	15	48540068	rs964611	15	48597514	A	C	0.15	1.664	0.009	0.00E+00	37527.1	-0.093	0.042	2.52E-02	-0.056	0.025	2.53E-02	4.70E-01	20
CA4	17	58237778	rs34820870	17	58244021	G	T	0.03	-0.462	0.021	6.1E-110	496.3	0.202	0.085	1.74E-02	-0.438	0.185	1.80E-02	1.64E-02	20
SLC16A1	1	113477052	rs3789592	1	113471400	A	G	0.41	0.123	0.008	4.34E-53	235.2	-0.178	0.031	6.28E-09	-1.443	0.266	5.61E-08	6.64E-01	20
ADRB2	5	148207176	rs2082395	5	148200600	A	G	0.42	0.126	0.008	6.31E-56	248.2	-0.119	0.030	8.83E-05	-0.944	0.248	1.42E-04	7.66E-01	5
KCNJ11	11	17409142	rs2074310	11	17421886	T	C	0.37	0.157	0.012	4.37E-38	166.5	0.340	0.032	5.50E-27	2.160	0.262	1.51E-16	6.53E-02	20
ATP1A1	1	116934086	rs6704439	1	116867616	A	C	0.27	0.041	0.009	4.39E-06	21.1	0.147	0.035	2.39E-05	3.567	1.148	1.88E-03	2.09E-01	8
SLC9A1	1	27459389	rs12751422	1	27493679	T	C	0.27	0.106	0.009	1.19E-32	141.6	-0.148	0.035	2.08E-05	-1.395	0.348	6.08E-05	9.72E-02	20
NR3C1	5	142736286	rs4912908	5	142791133	G	A	0.23	0.073	0.010	1.07E-13	55.2	0.094	0.038	1.20E-02	1.296	0.545	1.74E-02	2.92E-01	15
CACNA1H	16	1237506	rs35198836	16	1244631	T	C	0.22	0.149	0.011	2.95E-39	171.8	0.099	0.035	4.71E-03	0.668	0.241	5.69E-03	3.96E-01	20
AQP1	7	30929070	rs28362721	7	30957702	T	C	0.17	0.086	0.011	1.81E-15	63.3	0.115	0.041	4.93E-03	1.345	0.507	7.97E-03	5.12E-01	20
JUN	1	59248125	rs2716140	1	59472397	C	A	0.40	-0.228	0.008	3.5E-177	805.5	0.126	0.031	4.63E-05	-0.551	0.137	5.58E-05	9.09E-02	20
CA12	15	63643968	rs12909041	15	63743677	A	C	0.20	0.039	0.010	0.000114	14.9	0.090	0.038	1.92E-02	2.319	1.158	4.53E-02	1.08E-02	5
CACNA1D	3	53687586	rs9830632	3	53735766	G	A	0.29	-0.085	0.009	2E-22	94.9	0.207	0.034	9.24E-10	-2.427	0.468	2.14E-07	3.93E-01	20
CACNA2D2	3	50470954	rs62260815	3	50474624	A	G	0.11	-0.142	0.013	8.98E-29	123.9	-0.116	0.049	1.67E-02	0.814	0.348	1.94E-02	7.93E-02	20
PDE1B	12	54958078	rs1874308	12	54954356	A	T	0.30	0.429	0.009	0.00E+00	2301.7	-0.094	0.034	5.33E-03	-0.220	0.079	5.40E-03	7.35E-01	20
AHR	7	17362011	rs17700436	7	17167825	T	C	0.05	0.480	0.017	1.6E-178	811.7	-0.184	0.066	5.34E-03	-0.383	0.138	5.58E-03	7.08E-01	20
GPR35	2	241557762	rs2975788	2	241571858	G	A	0.48	0.293	0.009	6.2E-259	1181.6	0.065	0.030	3.29E-02	0.221	0.104	3.34E-02	7.59E-01	20
KCNJ2	17	68170501	rs9890133	17	68169005	G	A	0.11	-0.256	0.012	8.02E-94	422.2	0.094	0.047	4.61E-02	-0.367	0.185	4.72E-02	6.24E-01	20

Abbreviations: MR, Mendelian randomization, SNP, single nuclear polymorphism, eQTL, expression quantitative trait loci, se, standard error, SBP, systolic blood pressure, HEIDI, heterogeneity in dependent instruments, nsnp, number of SNPs for HEIDI test.

**Supplementary Table 4** Association between SLC12A2 and PDE1B eQTL SNP in blood with expression of other nearby genes

	Nearby gene	Chr	BP	Samples	eQTL SNP	SNP_BP	Effect_allele	Other_allele	Freq_Effect_allele	beta	se	p
SLC12A2	CTC-228N24.3	5	127347455	22495	rs17764730	127357526	T	C	0.227	-0.503	0.011	0.00E+00
	SLC12A2	5	127472419	31644	rs17764730	127357526	T	C	0.227	-0.186	0.009	3.20E-86
	FBN2	5	127794239	31684	rs17764730	127357526	T	C	0.227	-0.158	0.009	6.90E-63
	PRRC1	5	126872041	31684	rs17764730	127357526	T	C	0.227	-0.019	0.009	5.01E-02
	CTC-228N24.1	5	127158204	15590	rs17764730	127357526	T	C	0.227	0.013	0.014	3.37E-01
	HNRNPKP1	5	126847845	19056	rs17764730	127357526	T	C	0.227	-0.004	0.012	7.30E-01
	C5orf63	5	126393717	25262	rs17764730	127357526	T	C	0.227	0.003	0.011	7.81E-01
PDE1B	PDE1B	12	54958078	28131	rs1874308	54954356	A	T	0.289	0.429	0.009	0.00E+00
	NCKAP1L	12	54914610	28131	rs1874308	54954356	A	T	0.289	0.038	0.009	5.00E-05
	RP11-834C11.3	12	54484028	3827	rs1874308	54954356	A	T	0.289	-0.077	0.025	2.15E-03
	GPR84	12	54757250	28131	rs1874308	54954356	A	T	0.289	-0.026	0.009	4.92E-03
	SMUG1	12	54570653	27382	rs1874308	54954356	A	T	0.289	0.022	0.009	1.83E-02
	RP11-1049A21.2	12	54937392	4652	rs1874308	54954356	A	T	0.289	-0.045	0.023	5.07E-02
	RP11-968A15.8	12	54704641	3827	rs1874308	54954356	A	T	0.289	-0.047	0.025	6.18E-02
	HNRNPA1	12	54677424	23056	rs1874308	54954356	A	T	0.289	-0.014	0.010	1.66E-01
	NFE2	12	54690400	28131	rs1874308	54954356	A	T	0.289	0.013	0.009	1.79E-01
	RP11-968A15.2	12	54664623	4652	rs1874308	54954356	A	T	0.289	0.031	0.023	1.82E-01
	ATF7	12	53960919	11154	rs1874308	54954356	A	T	0.289	0.019	0.015	1.97E-01
	RP11-753H16.5	12	54804172	4018	rs1874308	54954356	A	T	0.289	0.029	0.025	2.34E-01
	ITGA5	12	54801144	28131	rs1874308	54954356	A	T	0.289	0.011	0.009	2.52E-01
	ZNF385A	12	54773999	28131	rs1874308	54954356	A	T	0.289	-0.010	0.009	2.67E-01
	RP11-834C11.4	12	54523254	21824	rs1874308	54954356	A	T	0.289	-0.011	0.011	2.86E-01
	PHC1P1	12	55806448	4526	rs1874308	54954356	A	T	0.289	-0.024	0.023	3.03E-01
	ATP5G2	12	54048851	28131	rs1874308	54954356	A	T	0.289	-0.009	0.009	3.60E-01
	HOXC5	12	54404387	27306	rs1874308	54954356	A	T	0.289	-0.008	0.009	3.91E-01
	COPZ1	12	54720309	28131	rs1874308	54954356	A	T	0.289	-0.006	0.009	5.00E-01
	HOXC4	12	54430264	22231	rs1874308	54954356	A	T	0.289	0.007	0.010	5.21E-01
	RP11-834C11.7	12	54473154	10394	rs1874308	54954356	A	T	0.289	-0.009	0.015	5.55E-01
	CBX5	12	54649305	27917	rs1874308	54954356	A	T	0.289	-0.004	0.009	6.70E-01
	TESPA1	12	55360166	21824	rs1874308	54954356	A	T	0.289	-0.004	0.011	6.97E-01
	GTSF1	12	54858560	11154	rs1874308	54954356	A	T	0.289	0.006	0.015	7.09E-01
	CALCOCO1	12	54113216	28131	rs1874308	54954356	A	T	0.289	-0.003	0.009	7.19E-01

Abbreviations: SNP, single nuclear polymorphism, eQTL, expression quantitative trait loci, se, standard error.

**Supplementary Table 5** MR association between expression of nearby genes of SLC12A2 and PDE1B in blood and risk of breast cancer and ER+ breast cancer

BC type	Target gene	Nearby gene	ProbeChr	Probe bp	topSNP	topSNP_bp	Effect allele	Other allele	Freq Effect allele	eQTL association			BC association			MR association			HEIDI Test		Posterior probability
										beta	se	p	beta	se	p	beta	se	p	p_HEIDI	nsnp	
Any BC	SLC12A2	CTC-228N24.3	5	127347455	rs6888037	127406259	G	T	0.21	-0.508	0.011	0.00E+00	0.027	0.007	1.09E-04	-0.054	0.014	1.15E-04	1.45E-01	20	77%
		SLC12A2	5	127472419	rs17764730	127357526	T	C	0.21	-0.186	0.009	3.20E-86	0.028	0.007	7.57E-05	-0.150	0.039	1.05E-04	1.56E-01	20	81.50%
		FBN2	5	127794239	rs79813368	127921198	A	G	0.05	1.262	0.013	0.00E+00	-0.003	0.011	7.71E-01	-0.002	0.009	7.71E-01	9.98E-01	20	0.33%
ER+ BC	SLC12A2	CTC-228N24.3	5	127347455	rs6888037	127406259	G	T	0.21	-0.508	0.011	0.00E+00	0.029	0.009	7.99E-04	-0.057	0.017	8.48E-04	1.70E-01	20	40.40%
		SLC12A2	5	127472419	rs17764730	127357526	T	C	0.21	-0.186	0.009	3.20E-86	0.029	0.009	6.96E-04	-0.158	0.048	8.67E-04	1.23E-01	20	40.46%
		FBN2	5	127794239	rs79813368	127921198	A	G	0.05	1.262	0.013	0.00E+00	-0.004	0.013	7.78E-01	-0.003	0.011	7.75E-01	1.00E+00	20	0.42%
	PDE1B	PDE1B	12	54958078	rs1874308	54954356	A	T	0.39	0.429	0.009	0.00E+00	0.030	0.008	3.38E-04	0.070	0.019	3.28E-04	2.37E-01	14	66.80%
		NCKAP1L	12	54914610	rs11609712	54890515	A	C	0.12	0.187	0.009	5.93E-100	0.010	0.009	2.69E-01	0.053	0.049	2.72E-01	1.03E-01	20	0.62%
		GPR84	12	54757250	rs3809161	54758330	A	G	0.50	0.222	0.008	3.93E-175	-0.015	0.008	6.21E-02	-0.067	0.036	6.16E-02	4.08E-01	20	1.67%
		SMUG1	12	54570653	rs2233921	54575800	A	C	0.32	-0.344	0.008	0.00E+00	-0.005	0.008	5.29E-01	0.014	0.022	5.31E-01	1.42E-01	20	0.34%

Abbreviations: MR, Mendelian randomization, SNP, single nuclear polymorphism, eQTL, expression quantitative trait loci, se, standard error, BC, breast cancer, HEIDI, heterogeneity in dependent instruments, nsnp, number of SNPs for HEIDI test.

**Supplementary Table 6** MR association between drug targeted gene expression in other tissue and overall risk of breast cancer

Tissue	Gene	Gene chr	Gene_start	topSNP	topSNP_bp	Effect allele	Other allele	Freq Effect allele	eQTL association			BC association			MR association			HEIDI Test	
									beta	se	p	beta	se	p	beta	se	p	p_HEIDI	nsnp
Adrenal Gland	KCNH2	7	150944961	chr7_150901391	150901391	C	T	0.452	-0.353	0.058	1.51E-09	0.017	0.010	1.09E-01	-0.047	0.031	1.22E-01	2.49E-01	20
	CACNA1H	16	1153121	chr16_1137931	1137931	T	C	0.408	-0.447	0.061	3.10E-13	-0.008	0.017	6.17E-01	0.019	0.037	6.18E-01	3.04E-01	12
Breast Mammary	GPR35	2	240605431	chr2_240621671	240621671	T	G	0.359	-0.378	0.041	9.62E-21	-0.025	0.014	7.97E-02	0.065	0.038	8.50E-02	8.58E-01	13
	PDE1B	12	54549350	chr12_54561540	54561540	C	T	0.693	0.310	0.027	9.15E-30	-0.038	0.011	6.26E-04	-0.122	0.037	1.06E-03	4.72E-01	11
Kidney Cortex	ACE	17	63477061	chr17_63482264	63482264	G	A	0.633	0.565	0.103	4.16E-08	-0.008	0.010	4.28E-01	-0.014	0.018	4.33E-01	NA	NA
Muscle Skeletal	GPR35	2	240605431	chr2_240621671	240621671	T	G	0.359	-0.438	0.037	2.14E-32	-0.025	0.014	7.97E-02	0.056	0.032	8.30E-02	6.89E-01	12
	SLC12A2	5	128083766	chr5_128146900	128146900	G	A	0.190	0.203	0.032	1.88E-10	-0.017	0.013	1.98E-01	-0.084	0.067	2.07E-01	6.30E-02	18
	KCNJ11	11	17385859	chr11_17374886	17374886	C	CCTTTAAC	0.218	-0.152	0.026	7.82E-09	-0.007	0.013	6.03E-01	0.043	0.083	6.04E-01	4.00E-01	13
	ASIC1	12	50057548	chr12_50068355	50068355	C	T	0.327	-0.189	0.034	1.99E-08	-0.007	0.012	5.68E-01	0.036	0.063	5.70E-01	1.45E-01	17
Ovary	GPR35	2	240605431	chr2_240621671	240621671	T	G	0.359	-0.523	0.063	8.97E-17	-0.025	0.014	7.97E-02	0.047	0.027	8.64E-02	6.79E-01	4
	KCNH2	7	150944961	chr7_150849357	150849357	T	C	0.033	-1.095	0.189	6.86E-09	-0.007	0.029	8.20E-01	0.006	0.026	8.20E-01	8.52E-01	16
	ASIC1	12	50057548	chr12_50089249	50089249	A	G	0.325	-0.391	0.069	1.75E-08	-0.009	0.012	4.32E-01	0.024	0.031	4.36E-01	2.16E-01	20
Small Intestine Terminal Ileum	GPR35	2	240605431	chr2_240621671	240621671	T	G	0.359	-0.261	0.038	4.18E-12	-0.025	0.014	7.97E-02	0.094	0.055	8.93E-02	1.61E-01	3
Uterus	NONE																		

**Supplementary Table 7** Causal association between systolic blood pressure (exposure) and risk of breast cancer (outcome)

Method	Number of SNPs	beta	se	OR	95% CI	p
GSMR	521	-0.0310	0.0171	0.969	0.938-1.002	0.0693
MR Egger	745	-0.0095	0.0043	0.991	0.982-0.999	0.0295
Weighted median	745	0.0004	0.0017	1.000	0.997-1.004	0.8306
Inverse variance weighted	745	-0.0002	0.0016	1.000	0.997-1.003	0.9178
Simple mode	745	0.0005	0.0061	1.000	0.989-1.013	0.9359
Weighted mode	745	0.0005	0.0038	1.000	0.993-1.008	0.8971

Abbreviations: se, standard error, SNP, single nucleotide polymorphism, OR odds ratio, CI confidence intervals

**Supplementary Table 8** Comparison of gene expression of SLC12A2 between breast cancer patients and controls in Expression Atlas

Experiment accession	Comparison (normal as reference)	Sample part	Log_2 fold change	Adjusted p-value
E-GEOD-68086	'breast carcinoma' vs 'normal'	blood platelet	-3.3	7.70E-24
E-GEOD-31138	invasive ductal carcinoma' vs 'normal'	breast	2.5	0.02863135
E-GEOD-45581	'non-inflammatory breast cancer' vs 'normal'	breast	-1.5	0.029033235
E-GEOD-54002	'breast cancer' vs 'normal'	mammary gland	-1.4	1.23364E-05
E-GEOD-38959	'breast cancer; breast' vs 'normal; breast'	breast	-1.3	0.017083027